Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EarCell is a regenerative therapy platform developed by Leonhardt Ventures for the treatment of hearing loss, specifically chronic noise-induced hearing loss. The therapy employs a multi-modal approach combining bioelectric stimulation, stem cell therapy, and the controlled release of growth factors. It utilizes a regeneration microstimulator and an implantable, programmable micro-infusion pump to deliver stem cells and modulate the expression of specific proteins, including Stromal cell-derived factor 1 (SDF-1), Insulin-like growth factor 1 (IGF-1), Epidermal growth factor (EGF), Hepatocyte growth factor (HGF), Platelet-derived growth factor (PDGF), and Vascular endothelial growth factor (VEGF). These factors work synergistically to recruit progenitor cells and promote the regeneration of sensory hair cells within the cochlea.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EarCell.